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Abstract We identified a predominant clone of Clostridium
difficile PCR ribotype 002, which was associated with an
increased sporulation frequency. In 2009, 3,528 stool
samples from 2,440 patients were tested for toxigenic C.
difficile in a healthcare region in Hong Kong. A total of 345
toxigenic strains from 307 (13.3%) patients were found.
Ribotype 002 was the predominant ribotype, which consti-
tuted 35 samples from 29 (9.4%) patients. The mean
sporulation frequency of ribotype 002 was 20.2%, which
was significantly higher than that of the 56 randomly
selected ribotypes other than 002 as concurrent controls
(3.7%, p<0.001). Patients carrying toxigenic ribotype 002
were more frequently admitted from an elderly home (p=
0.01) and received more β-lactam antibiotics in the
preceding 3 months compared with the controls (p=0.04) .
The identification of toxigenic ribotype 002 in 2009 was
temporally related to a significant increase in both the
incidence of toxigenic C. difficile from 0.53 to 0.95 per
1,000 admissions (p<0.001) and the rate of positive
detection from 4.17% to 6.28% (p<0.001) between period
1 (2004–2008) and period 2 (2009). This finding should alert
both the physician and the infection control team to the
establishment of and possible outbreaks by ribotype 002 in
our hospitals, as in the case of ribotype 027.
Introduction
Clostridium difficile is an anaerobic, Gram-positive, spore-
forming bacillus which causes gastrointestinal diseases
ranging from antibiotic-associated diarrhea to pseudomem-
branous colitis. Though community-acquired infection can
occur, most cases are found in the hospital and long-term
care facilities [1]. The fecal colonization rate in ambulatory
individuals is up to 2% [2, 3] and this increased to 15–30%
among hospitalized patients due to the acquisition from
healthcare workers and the hospital environment [4]. About
15–60% of the colonized patients develop symptomatic
diarrhea during hospitalization [5–7], which may increase
the nosocomial transmission of C. difficile with hospital
outbreaks. Recently, a virulent strain identified as PCR
ribotype 027, toxinotype III, or North American pulse-field
type 1 has emerged to cause severe colitis, leading to a high
mortality rate [8–10]. The mechanism of increased viru-
lence is still under investigation, but it may be related to the
18-bp deletion and single-base-pair deletion at position 117
in the toxin regulator gene (tcdC), leading to the hyperpro-
duction of toxins A and B [11, 12]. In addition, increased
sporulation frequency of certain epidemic strains of C.
difficile PCR ribotype 027 may also contribute to its better
survival and nosocomial spread [13, 14]. Sporulation
occurs when the ability to maintain vegetative growth has
failed and facilitates the transmission of C. difficile in the
healthcare setting, as the spores remain infective and persist
in the environment for many months [15].
A sporadic case of C. difficile PCR ribotype 027 was
reported in Hong Kong in 2008 [16]. In response to this
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emerging infectious agent, further investigation was
performed on all C. difficile isolates in a healthcare
region in Hong Kong. We also conducted a retrospective
review of the clinical and epidemiological data related to
the different ribotypes of toxigenic C. difficile isolated in
2009. The findings and their potential implications in
disease transmission and infection control practice are
discussed.
Materials and methods
Setting
A surveillance program was conducted in a regional
microbiology laboratory in Hong Kong. The laboratory
provided service to a healthcare network of five
hospitals, including one acute care university teaching
hospital with 1,400 beds and four chronic care hospitals
with 110 to 524 beds. The hospital network provided
clinical service to a population of approximately 0.53
million people. Between 1 January 2009 and 31
December 2009, stool specimens from hospitalized
patients sent for culture and cytotoxin assay of C.
difficile were performed by our routine service protocol
as usual, but the toxigenic strains were further character-
ized by molecular tests. The incidence of toxigenic C.
difficile per 1,000 admissions and the rate of detection
identified between period 1 (2004 and 2008) and period 2
(2009) were analyzed using databases of the laboratory
information and hospital record system.
Bacterial culture for C. difficile
Liquid or semisolid stool samples were tested within
24 h of receipt. The samples were inoculated onto
cycloserine–cefoxitin–fructose agar (CCFA) containing
4% proteose peptone, 0.5% Na2HPO4, 0.1% KH2PO4,
0.01% MgSO4, 0.2% NaCl, 0.6% fructose, 1.5% agar at
pH 7.4 (#CM0601, Oxoid, UK), with added selective
supplement containing 250 mg/L D-cycloserine, 8 mg/mL
cefoxitin (#SR0096, Oxoid, UK), and 7% horse blood.
Culture plates were incubated anaerobically at 35°C to
37°C for 48 h. Obligatory anaerobic, large Gram-positive
bacilli that were isolated from the CCFA and were
susceptible to 5 μg of vancomycin were presumptively
identified as C. difficile. The identification was confirmed
by the Vitek® Anaerobe Identification Card (ANI) (bio-
Mérieux, Inc., USA). Antimicrobial susceptibility testing
against metronidazole, vancomycin, and ciprofloxacin
were performed for selected strains using Etest strips
according to the manufacturer’s instructions (AB Biodisk,
Sweden).
Cell culture cytotoxicity neutralization assay
Approximately 3 to 5 g of stool was suspended in 5 ml of
phosphate-buffered saline (PBS) in a 1:2 dilution at a pH
level of 7. The sample was centrifuged at 3,000 rpm for
55 min to produce a supernatant, which was subsequently
transferred into eppendorf tubes and centrifuged at
13,000 rpm for 15 min at 4°C to clarify the supernatant.
The supernatant was passed through a 0.22-μm-pore-size
membrane filter. A toxin-producing C. difficile strain
(UKEQAS QC 6109) was used as the positive control for
the cell culture cytotoxicity neutralization assay (CCCNA),
which was performed in sterile 96-well plates coated with
the HeLa cell line as previously described [16]. In addition
to the direct detection of cytotoxin from stool filtrates,
CCCNAwas also performed on the stationary-phase culture
supernatant of each C. difficile isolate. C. difficile isolates
were subcultured to brain heart infusion broth and
incubated anaerobically for 96 h. Culture supernatant was
subjected to CCCNA as for stool filtrate with the same
interpretation criteria as previously described [16].
PCR ribotyping
DNA was extracted from C. difficile colonies using alkaline
lysis as described previously [17]. Polymerase chain reaction
(PCR) ribotyping was performed according to the method
described by Bidet et al. [18]. After the electrophoresis of
PCR products, the phylogenetic tree was constructed using
BioNumerics v6.0 software (Applied Maths, Belgium).
slpA typing
slpA typing was performed for selected strains belonging to
the same ribotype according to Joost et al. [19]. The
purified PCR product was subjected to cycle sequencing by
ABI BigDye terminator v1.1 (Applied Biosystems, Foster
City, USA) and the resulting slpA sequence was compared
to those in the NCBI database by using Nucleotide BLAST.
Aerotolerance sporulation experiment
The Miles and Misra method was adopted to study all PCR
ribotype 002 isolates [20]. C. difficile was subcultured to C.
difficile agar (Mast Group Ltd., Merseyside, UK) and
incubated at 37°C anaerobically for 72 h. Bacterial
suspension was prepared in saline to a turbidity of McFar-
land standard 0.5, followed by serial dilutions in saline to
101–104. Twenty microliters of each bacterial suspension
with dilutions from 102 to 104 were transferred to three
sectors of 12 blood agar plates from a height of 2.5 cm. The
inoculum was spread over an area of 1.5–2.0 cm diameter.
One set of agar plates (six blood agar plates) were incubated
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for 72 h at 37°C anaerobically and the other set of agar plates
(six blood agar plates) were incubated for 48 h at 37°C
aerobically, followed by a further incubation of 72 h at 37°C
anaerobically. The sporulation frequency (the spore/total cell
ratio), expressed as a percentage, was determined by dividing
the average cell count of the second set over the first set. To
rule out cross-contamination by other Clostridium species in
the experiment [21], PCR for C. perfringens and C. difficile
was performed on bacterial suspensions and colonies
according to previously described methods [22, 23].
ELISA for the detection of C. difficile toxins A and B
Toxins A and B were measured by the C. difficile TOX A/B
II™ kit (TechLab, the Netherlands), according to the
manufacturer’s instructions. All strains belonging to the
PCR ribotype 002 were subcultured into brain heart infusion
broth and incubated for 72 h anaerobically. Bacterial
suspension was centrifuged at 3,000×g for 10 min and
50 μl of supernatant was mixed with 200 μl of diluent
supplied in the kit. One drop (50 μl) of conjugate was added
to the well of a microassay plate with immobilized affinity-
purified polyclonal goat antibody against toxins A and B.
The 100 μl diluted sample was transferred and mixed with
the conjugate in the wells. The plate was incubated at 37°C
for 50 min, washed four times with 1X wash solution,
followed by the addition of 100 μl substrate solution. Stop
solution was added to terminate the reaction after 5 min of
incubation at room temperature. The resulting yellow color
change was quantified by measuring the optical density
450 nm/620 nm. An A450/620 value of 1.0 corresponded to
1 U of the total amount of toxins (A and B).
Epidemiology of PCR ribotype 002 in our healthcare region
Patients with toxin-producing C. difficile were assessed by
infection control nurses for symptomatology. Case records
were reviewed if the patients had been discharged. Patients
with diarrhea at the time of specimen collection were
classified as having symptomatic infection, while those
without diarrhea were classified as having asymptomatic
colonization. Patients with symptomatic infection were further
classified as having healthcare-associated infection, of which
the development of symptoms started more than 48 h after
admission to the hospital or within 4 weeks after discharge
from the hospital, or community-associated infection, of
which the development of symptoms started within 48 h after
admission to the hospital or more than 12 weeks after
discharge from the hospital, as previously described
[24, 25]. When symptoms developed 4–12 weeks after
hospital discharge, the association was indeterminate. The
disease severity was stratified according to a scoring system
described previously [26]. Briefly, two points were given to
2440 patients (3528 stool samples)
Toxigenic C. difficile:
307 patients (345 samples)a
Non toxigenic C. difficile:
337 patients (570 samples)
Culture negative:
1796 patients (2613 samples)
PCR ribotype 002
29 patients (35 samples)
Symptomatic infection:
17(58.6%) patients
Colonization:
12 (41.4%)patients
Fig. 1 Workup for Clostridium
difficile PCR ribotype 002 in a
healthcare region in Hong Kong
(1 January 2009 to 31 December
2009). a169 strains from 145
patients were found to have
cytotoxin production by cell
culture cytotoxicity neutraliza-
tion assay (CCCNA) from both
stool filtrates and C. difficile
isolates. Another 176 strains
from 162 patients had negative
cytotoxin production in stool
filtrates but positive toxin pro-
duction in the culture superna-
tant of C. difficile isolates
Table 1 Ribotype distribution of toxin-producing strains of Clostrid-
ium difficile among 307 patients in Hong Kong
Total number of
strains (%)
Total number of
patients (%)
PCR ribotype 002a 35 (10.1%) 29 (9.4%)
PCR ribotype og39b 13 (3.8%) 11 (3.6%)
PCR ribotype 012 8 (2.3%) 7 (2.3%)
PCR ribotype 014 4 (1.2%) 4 (1.3%)
PCR ribotype 017 2 (0.6%) 2 (0.7%)
PCR ribotype 001 1 (0.3%) 1 (0.3%)
PCR ribotype 027 0 0
Other pattern 242 (70%) 221 (72%)c
Non-typable 40 (11.6%) 32 (10.4%)
Total 345 307
a PCR ribotype 002 constituted 55.6% (35/63) of strains and 53.7% (29/54)
of patients with known ribotyping results
b This cluster of strains was identified by slpA typing
c Using 80% similarity in the dendrogram as the cutoff value, there were
106 distinct patterns with no more than eight isolates in each pattern
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Ribotyping
10
0
90807060504030
Ribotyping
Marker
Standard Netherlands_117
Standard Netherlands_070
Standard Netherlands_078
Standard Netherlands_012
Standard Netherlands_029
Standard Netherlands_075
Standard Netherlands_023
Standard Netherlands_027
Standard Netherlands_081
Standard Netherlands_046
Standard Netherlands_001
Standard Netherlands_053
Standard Netherlands_087
Standard Netherlands_014
Standard Netherlands_077
Standard Netherlands_020
Standard Netherlands_095
Standard Netherlands_015
Standard Netherlands_017
Standard Netherlands_056
Standard Netherlands_003
Standard Netherlands_106
Standard Netherlands_002
229
398
531
610
536
171
538
386
330
412
457
445
486
092
384
424
476
339
147
570
473
113
149
213
586
628
535
580
627
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patients with endoscopic confirmation of pseudomembranous
colitis or those requiring intensive care support. One point
each was given for age >60 years, temperature >38.3°C,
albumin level <2.5 mg/dL, and peripheral WBC count
>15,000 cells/mm3 within 48 h of symptom onset. Patients
with two points or more were considered as having “severe C.
difficile-associated diarrhea (CDAD)”. Otherwise, the patient
was stratified as having “C. difficile infection”. The demo-
graphics of the patients with C. difficile ribotype 002 and 56
randomly selected patients with PCR ribotypes other than 002
were compared.
Sporulation frequency and toxin level of C. difficile PCR
ribotype 002
The toxin level of all strains of C. difficile PCR ribotype 002
were determined by ELISA. The sporulation frequency of C.
difficile PCR ribotype 002 was measured by the quantitative
method described above. The correlation between the
sporulation frequency and toxin level was assessed. The
sporulation frequencies and toxin levels of the strains isolated
from patients with symptomatic infection were compared to
those from asymptomatic patients. The sporulation frequency
was tested in 56 randomly selected strains of PCR ribotypes
other than 002 (one strain of 001, six strains of 012, three
strains of 014, two strains of 017, eight strains of og39, and 36
strains of other patterns) as the control.
Statistical analysis
Fisher’s exact test and Student’s t-test were used in the
analysis, where appropriate. Changes in the incidence of
toxigenic C. difficile per 1,000 admissions between period 1
(2004–2008) and period 2 (2009) was analyzed by Poisson
regression. Correlation between sporulation frequency and
toxin level was assessed by Spearman’s rank correlation
coefficient. All reported p-values were two-sided. A
p-value of <0.05 was considered to be statistically
significant. Computation was performed using the Statisti-
cal Package for the Social Sciences (SPSS) version 15.0 for
Windows.
Results
Between 1 January 2009 and 31 December 2009, a total of
3,528 stool samples from 2,440 patients were tested for C.
difficile culture and cytotoxin assay. A total of 169 samples
from 145 (5.9%) patients were found to have cytotoxin
production by CCCNA from both stool filtrates and C.
difficile isolates. Another 176 samples from 162 (6.6%)
patients had negative cytotoxin production in stool filtrates
but positive toxin production in the culture supernatant of
C. difficile isolates (Fig. 1). A total of 345 toxigenic C.
difficile strains from 307 (12.5%) patients were further
tested for ribotyping and the results are listed in Table 1. All
PCR ribotypes concurred with slpA typing results. PCR
ribotype 002 was the most predominant ribotype, consti-
tuting 35 strains from 29 (9.4%) patients with toxin-
producing C. difficile. The dendrogram of C. difficile PCR
ribotype 002 is shown in Fig. 2. All 35 strains of PCR
ribotype 002 were resistant to ciprofloxacin (minimum
inhibitory concentration [MIC]>32 μg/ml). The MIC50 of
metronidazole and vancomycin were 0.5 μg/ml and
0.75 μg/ml, respectively, whereas the MIC90 were
0.75 μg/ml and 1.5 μg/ml, respectively. The change in
incidence of toxigenic C. difficile per 1,000 admissions and
the rate of positive detection in our healthcare region from
2004 to 2009 are shown in Fig. 3. There was a significant
increase in both the incidence of toxigenic C. difficile from
0.53 to 0.95 per 1,000 admissions (p<0.001) and the rate of
positive detection from 4.17% to 6.28% (p<0.001) between
period 1 (2004–2008) and period 2 (2009).
Epidemiology of PCR ribotype 002 in our healthcare region
During the study period, a total of 29 patients shed C.
difficile ribotype 002 in the stool. There were 20 males and
9 females, with a median age of 76 years (range
14–97 years). Eleven (37.9%) patients were old age persons
home residents. Symptomatic infection was diagnosed in 17
(58.6%) patients, while ten of them had severe CDAD
according to the scoring system (Table 2). All 17 patients
with symptomatic infection were defined as healthcare-
associated infection. Colonization of C. difficile was found
in 12 (41.4%) patients. Most of the patients (24, 82.8%)
were managed in the medical ward, while three patients
were managed in the surgical ward, one patient in the
emergency department, and one patient in the pediatric and
adolescent unit. These patients were located in 20 different
wards from three different hospitals (one acute care and two
chronic care hospitals) without any epidemiological link-
age. There were five patients with repeated isolation of C.
difficile during the same episode of hospitalization, among
whom four patients had two episodes and one patient had
three episodes. Among these five patients, three had
symptomatic infection and one had asymptomatic coloni-
zation. The other progressed from asymptomatic coloniza-
tion to symptomatic infection during hospitalization. The
demographic characteristics of patients with C. difficile
PCR ribotype 002 and ribotypes other than 002 are
illustrated in Table 3. Patients carrying toxigenic C. difficile
Fig. 2 Dendrogram of Clostridium difficile PCR ribotype 002 among
29 patients. Note: the strain number among 29 patients’ isolates and
the standard strains of different PCR ribotypes from the Netherlands
are listed

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PCR ribotype 002 were more frequently admitted from an
elderly home (p=0.01) and received more β-lactam anti-
biotics in the preceding 3 months (p=0.04).
Sporulation frequency and toxin level of C. difficile PCR
ribotype 002
There is no statistically significant correlation between the
sporulation frequency and the measured toxin levels of the
C. difficile isolates (Spearman’s rho 0.0311, p=0.858). The
mean sporulation frequency of 35 strains of C. difficile PCR
ribotype 002 was 20.2%, which was significantly higher
than that of the 56 randomly selected PCR ribotypes other
than 002 (3.7%, p<0.001). Among the 23 strains of C.
difficile PCR ribotype 002 isolated from patients with
symptomatic infection, the mean sporulation frequency was
significantly higher than 12 strains of PCR ribotype 002
cultured from patients with asymptomatic colonization
(28.9% vs. 3.5%, p=0.02). The mean levels of toxin
production by ELISA among strains collected from patients
with asymptomatic colonization and symptomatic infection
were 96.13 U/ml and 123.85 U/ml, respectively (p=0.29).
Subgroup analysis for the C. difficile isolated from
symptomatic patients with or without severe CDAD
showed no statistically significant difference in terms of
sporulation frequency and toxin production.
Discussion
C. difficile has become a re-emerging pathogen since the
outbreak of a hypertoxigenic strain of PCR ribotype 027 in
North America and Europe since 2003 [8, 10, 11]. This was
followed by its global dissemination to the other continents
in 2008 [27]. On the other hand, C. difficile PCR ribotypes
other than 027 have also been increasingly reported
recently. PCR ribotype 078 has been implicated in
community-associated C. difficile infection in the Nether-
lands [24], while PCR ribotypes 001 and 018 were the most
commonly identified ribotypes in the healthcare facilities in
Germany, the UK, and Italy [28–30]. Although C. difficile
ribotype 027 has also been reported in Hong Kong in 2008
[16], our present study showed that PCR ribotype 002 was
the most predominant strain and constituted 56% (35 out of
63 typed strains with well-characterized PCR ribotyping) of
the C. difficile strains isolated in 2009. This finding might
explain the significant increase in the positive detection rate
of toxigenic C. difficile and the incidence of toxigenic C.
difficile per 1,000 admissions observed in 2009 as
compared to the baseline data between 2004 and 2008.
C. difficile PCR ribotype 002 was commonly found in
patients with both symptomatic infection and asymptomatic
colonization. The mean sporulation frequency (20%) of our
strains was significantly higher than the other PCR
ribotypes in our locality, but was comparable to that of
the epidemic strains of C. difficile PCR ribotype 027 [13].
Since the epidemic strains of C. difficile were reported
to have an inherently increased sporulation frequency
[13, 31], and the transmission of C. difficile in the
healthcare facilities was mediated primarily by spores
found in the environment or carried by healthcare workers
[32, 33], C. difficile PCR ribotype 002 might, thus, become
an epidemic strain and contribute to hospital outbreaks. In
fact, all 17 symptomatic patients carrying PCR ribotype
002 had healthcare-associated C. difficile infection. Fur-
thermore, as the proportion of patients residing in elderly
homes was significantly higher among those with PCR
ribotype 002 than those with other ribotypes, further
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investigations should be conducted in order to determine
whether elderly homes might serve as an epidemic center
amplifying this particular ribotype in our locality.
Interestingly, C. difficile PCR ribotype 002 isolated from
patients with symptomatic infection had a significantly
higher rate of sporulation, but not to the level of toxin
production in vitro. Furthermore, there was no correlation
between toxin production and sporulation. Our finding was
in concordance with a recent study which suggested toxin
production and sporulation to be opposite survival strate-
gies for C. difficile in response to nutrient limitation by
demonstrating an inverse correlation between toxin level
and spore count in stationary-phase cultures [34]. However,
a more recent analysis of a hypervirulent strain of C.
difficile exhibited an increased sporulation as well as toxin
production [14]. Since sporulation and toxin production is a
complex process [35], and the disease severity of C.
difficile is also determined by host factors such as the age,
Table 3 Demographic characteristics of patients with culture isolation of Clostridium difficile ribotype 002 and non-ribotype 002 in Hong Kong
Clostridium difficile
ribotype 002 (n=29)
Clostridium difficile
ribotype other
than 002b (n=56)
p-value
Age (mean±SD) 68.1±25.5 58.3±26.2 0.97
Sex (M/F) 20/9 33/23 0.37
Residence in elderly home 11 (37.9%) 7 (12.5%) 0.01a
Patients with
Malignancy 12 (41.4%) 20 (35.7%) 0.61
Organ transplant 2 (6.9%) 5 (8.9%) 1.0
Cardiopulmonary condition 9 (31.0%) 10 (17.9%) 0.18
Renal failure 5 (17.2%) 7 (12.5%) 0.55
Cerebrovascular accident 5 (17.2%) 6 (10.7%) 0.40
Diabetes mellitus 4 (13.8%) 9 (16.1%) 0.78
Patients with
Asymptomatic colonization 12 (41.4%) 26 (46.4%) 0.66
Severe CDADc 7/17 (41.2%) 13/30 (43.3%) 0.90
Number of hospitalizations in
the past year, median (interquartile range)
6 (4–12) 5.5 (2–12.75) 0.52
Number of patients with isolation of toxigenic
C. difficile in the past year
3 (10.3%) 8 (14.3%) 0.74
Antibiotic therapy in the week preceding
the culture of C. difficile
21 (72.4%) 34 (60.7%) 0. 29
Days of antibioticsd received by patients in
the past 3 months (mean±SD)
β-lactams 23.7±17.9 16.2±14.6 0.04
Fluoroquinolones 2.6±5.1 5.6±10.0 0.14
Clindamycin 0 0.2±1.2 0.35
Number of patients using proton pump inhibitors
Within 90 days 14 (48.3%) 19 (33.9%) 0.24
91–180 days 8 (27.6%) 12 (21.4%) 0.59
181–365 days 5 (17.2%) 10 (17.9%) 1
Mean (range) days between the identification
of C. difficile and admission
35.2 (1–376) 31.4 (0–416) 0.99
30-day survival after the identification of
C.difficile and admission
3 (10.3%) 6 (10.7%) 0.96
a Odds ratio 1.89; 95% confidence interval 1.04–3.42
b Patients with Clostridium difficile ribotype 001 (n=1), 012 (n=6), 014 (n=3), 017 (n=2), og39 (n=8), and unrecognized ribotype (n=36) were randomly
selected as the control
c Severe CDAD (C. difficile-associated diarrhea) is defined according to the disease score, as previously described [26]
d Penicillin group included ampicillin, amoxicillin–clavulanate, ampicillin–sulbactam, ticarcillin–clavulanate, piperacillin, and piperacillin–tazobactam;
cephalosporin group included cefazolin, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, cefoperazone, cefoperazone–sulbactam, cefepime; carbapenem
group included imipenem–cilastatin, meropenem, and ertapenem; fluoroquinolones included ciprofloxacin, levofloxacin, and moxifloxacin
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underlying diseases, and levels of toxin-neutralizing anti-
bodies [36, 37], the relationship between sporulation
frequency and disease severity remains to be elucidated.
The emergence of C. difficile with an inherently
increased sporulation such as PCR ribotypes 027, 001,
and 002 poses a great challenge to the infection control
team. There is increasing evidence that the use of
fluoroquinolones is a major risk factor for CDAD in the
hospital and long-term care facilities [38–42]. Similar to the
other emerging PCR ribotypes of C. difficile, all of our
ribotype 002 strains were resistant to fluoroquinolones with
an MIC>32 μg/ml against ciprofloxacin. Since the use of
fluoroquinolones is increasing globally and locally [43, 44],
our antimicrobial stewardship program should no longer
target broad-spectrum antimicrobial agents only and should
extend to include fluoroquinolones as well [45, 46]. Of
note, patients carrying C. difficile PCR ribotype 002 were
more frequently found to have used β-lactam antibiotics,
including penicillin, cephalosporin, and carbapenem, in the
preceding 3 months to our analysis (Table 3). As most of
the β-lactams have a relatively lower MIC against C.
difficile [47–49], strains with inherently increased sporula-
tion, such as PCR ribotype 002, may survive better than
poorly sporulating ribotypes, despite β-lactam antibiotics
therapy. The waterless alcohol-based hand rub, which has
been highly advocated in the healthcare setting for hand
hygiene, was not effective against the spores of C. difficile
in the hands [50, 51], even with directly observed hand
hygiene practice [52]. Therefore, a timely laboratory
diagnosis to recognize this high-risk strain would facilitate
strategic infection control interventions, which should
include the early identification of symptomatic cases for
contact precautions with single-room isolation and thorough
environmental cleaning with chlorine-based germicides in
order to inactivate C. difficile spores. In fact, the use of non-
chlorine-based cleaning agents has been associated with a
paradoxical increase in sporulation, which may further
enhance the nosocomial transmission of C. difficile [31,
53]. A close collaboration between the microbiology
laboratory and the infection control team is essential for the
successful prevention of nosocomial outbreaks of C. difficile
PCR ribotype 002 in our healthcare region.
There were several limitations to this study. Firstly, as
there was no standardized guideline on when to order stool
testing for C. difficile in our hospital, the population of our
samples may have been biased. This might contribute to the
apparently higher proportion of asymptomatic colonization
of ribotype 002 among our population than that previously
reported for C. difficile in general [2–4]. However, the exact
asymptomatic colonization rate of ribotype 002 has not
been clearly documented elsewhere. Secondly, we only had
23 (20%) out of 116 control strains available for the full
panel of PCR ribotyping [54]. There might be a possibility
of missing some important PCR ribotypes in our series.
However, among 221 patients with unrecognized PCR
ribotypes, there were 106 distinct patterns and no major
cluster. Thirdly, we could not retrieve the archived strain
from the early period and, thus, the origin of this C. difficile
PCR ribotype 002 could not be ascertained. From the
epidemiological perspective, the incidence of toxigenic C.
difficile remained static (0.53 per 1,000 admissions)
between 2004 and 2008, but it suddenly increased to 0.95
per 1,000 admissions in 2009. Although the incidence was
lower than some centers in Europe and was still within an
acceptable limit of less than 5 cases per 1,000 admissions as
recommended by some experts [55, 56], an 80% upsurge
should alert both the physician and the infection control
team to possible outbreaks of ribotype 002 before it could
become established in our hospitals, as in the case of C.
difficile PCR ribotype 027.
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